Bayer Aktiengesellschaft Q3 2025 Earnings Recap

BAYN.DE Q3 2025 November 14, 2025

Get alerts when BAYN.DE reports next quarter

The company reported a slight increase in sales and a 7% year-over-year gain in core EPS to EUR 4.29, while navigating challenges in Consumer Health and ongoing regulatory effects in Crop Science.

Earnings Per Share Beat

$0.58 vs $0.37 est.

+55.7% surprise

Revenue Miss

9660000000 vs 9785281041 est.

-1.3% surprise

Market Reaction

1-Day -1.62%

5-Day -2.89%

30-Day +23.72%

See BAYN.DE alongside your other holdings

Add to your portfolio — free

Key Takeaways

Core EPS increased by 7% year-over-year to EUR 4.29, reflecting operational efficiency gains.
While Crop Science showed resilience with a 9% growth in corn sales, regulatory effects have led to a 2% decline in the Core Crop Protection business.
Pharmaceuticals segment propelled by strong sales of Nubeqa and Kerendia, up 60% and 80% respectively, despite pressures on Eylea.
Anticipate challenges in Consumer Health, revising full-year sales growth expectations downward due to a soft market environment.
FDA approval for Lynkuet and progress in cell and gene therapies indicate ongoing commitment to innovation and future growth prospects.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit BAYN.DE on AllInvestView.